Value of FLT PET/CT in Radium-223 Therapy of mCRPC Patients

Rigshospitalet, Denmark6 enrolled

Overview

The aim of the study is to investigate whether positron emission tomography (PET) using the tracer 18F-Fluorothymidine (FLT) can provide information on proliferative activity in bone marrow of patients receiving Radium 223 therapy and potentially be a predictive marker of hematological toxicity

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

Metastatic Prostate Carcinoma

Interventions

FLT PET/CTOTHER

FLT PET/CT before first series of Radium-223 and after 2 series

Eligibility

Sex: MALE

Medical Language ↔ Plain English

Inclusion Criteria: * Metastatic castration resistant prostate cancer * Eligible for Radium-223 therapy * Informed consent Exclusion Criteria: * Inability to understand study protocol * Extensive metastatic involvement of the axial skeleton ("superscan" on bone scintigraphy)

Locations (1)

Rigshospitalet

Copenhagen, Denmark

Outcomes

Primary Outcomes

Uptake of FLT in hematological bone marrow

Time frame: 3 months

Secondary Outcomes

Occurrence of hematological toxicity

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.